Psoriasis and psoriasiform lesions induced by TNFα antagonists: The experience of a tertiary care hospital from northern Spain

Rheumatology International

Volumn 32, Issue 12, 2012, Pages 3779-3783

  López Robles, Alejandra ^a   Queiro, Rubén ^a   Alperi, Mercedes ^a   Alonso, Sara ^a   Riestra, José L ^a   Ballina, Javier ^a  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

Anti TNF drugs; Cumulated incidence; Palmoplantar pustulosis; Psoriasis

Indexed keywords

ADALIMUMAB; CEPHALOSPORIN; CLOBETASOL; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PERMANGANATE POTASSIUM; SALAZOSULFAPYRIDINE;

ADULT; AGED; ANKYLOSING SPONDYLITIS; ARTICLE; CALCULATION; CLINICAL FEATURE; COHORT ANALYSIS; DISEASE COURSE; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; HUMAN; INCIDENCE; LATENT PERIOD; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; PUSTULE; PUSTULOSIS PALMOPLANTARIS; PUVA; RHEUMATOID ARTHRITIS; SAPHO SYNDROME; SKIN MANIFESTATION; SPAIN; SPONDYLARTHRITIS; TERTIARY HEALTH CARE; TREATMENT RESPONSE; UNIVERSITY HOSPITAL;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; FEMALE; HUMANS; IMMUNOGLOBULIN G; INCIDENCE; MALE; MIDDLE AGED; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; RHEUMATIC DISEASES; SPAIN; TERTIARY HEALTHCARE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84872271017     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-011-2265-4     Document Type: Article

References (20)

1. Wollina U, Hansel G, Koch A et al (2008) Tumor necrosis factoralpha inhibitor-induced psoriasis or psoriasiform exanthemata: Wrst 120 cases from the literature including a series of six new patients. Am J Clin Dermatol 9:1-14
2. Ko JM, Gottlieb AB, Kerbleski JF (2009) Induction and exacerbation of psoriasis with TNF-blockade therapy: A review and analysis of 127 cases. J Dermatol Treat 20:100-108
3. Collamer AN, Batafarro DF (2010) Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: Clinical features and possible immunopathogenesis. Semin Arthritis Rheum 40:233-240
4. Harrison MJ, Dixon WG, Watson KD et al (2009) Rates of newonset psoriasis in patients with rheumatoid arthritis receiving antitumor necrosis factor therapy: Results from the British society for rheumatology biologics register. Ann Rheum Dis 68:209-215
5. Santos-Juanes J, Galache C (2010) Psoriasiform skin reactions during treatment with etanercept. Actas DermosiWliorg 101(Suppl 1):106-110
6. Wendling D, Balblanc JC, Briancon D et al (2008) Onset or exacerbation of cutaneous psoriasis during TNF-alpha antagonist therapy. Jt Bone Spine 75:315-318
7. Swkakis PP, Iliopoupoulos A, Elezoglou A et al (2005) Psoriasis induced by anti-tumor necrosis factor therapy: A paradoxical adverse reaction. Arthritis Rheum 52:2513-2518
8. Mourao AF, Rustin M, Isenberg D (2010) Exacerbation of psoriatic skin lesions in patients with psoriatic arthritis receiving anti-tumor necrosis factor-alpha therapy: Description of 3 cases and review of the literature. Clin Exp Rheumatol 28:408-410
9. Krueger G, Callis K (2004) Potential of tumor necrosis factor inhibitor in psoriasis and psoriatic arthritis. Arch Dermatol 140:218-225
10. Carter JD, Gerard HC, Hudson AP (2008) Psoriasiform lesions induced by tumor necrosis factor antagonists: A skin-deep medical conundrum. Ann Rheum Dis 67:1181-1183
11. de Gannes GC, Ghoreishi M, Pope J et al (2007) Psoriasis and pustular dermatitis triggered by TNF-α inhibitors in patients with rheumatologic conditions. Arch Dermatol 143:223-231
12. Sari I, Akar S, Birlik M et al (2006) Anti-tumor necrosis factor-?-induced psoriasis. J Rheumatol 33:1411-1414
13. Collamer AN, Guerrero KT, Henning JS et al (2008) Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: A literature review and potential mechanisms of action. Arthritis Rheum 59:996-1001
14. Aslanidis S, Pyrpasopoulou A, Douma S et al (2008) Tumor necrosis factor-? antagonist-induced psoriasis: Yet another paradox in medicine. Clin Rheumatol 27:377-380
15. Avila Alvarez A, García-Alonso L, Solar Boga A et al (2009) Flexural psoriasis induced by infliximab and adalimumab in a patient with Crohn's disease. An Pediatr (Barc) 70:278-281
16. Grinblat B, Scheinberg M (2008) The enigmatic development of psoriasis and psoriasiform lesions during anti-TNF therapy: A review. Semin Arthritis Rheum 37:251-255
17. Cohen JD, Bournerias I, BuVard V et al (2007) Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: A case series. J Rheumatol 34:380-385
18. Laurindo IM, Scheinberg M (2008) Why do some biologic agents induce psoriasis or psoriasiform lesions? Nat Clin Pract Rheumatol 4:168-169
19. Massara A, Cavazzini PL, Trotta F (2006) In SAPHO syndrome anti-TNF-? therapy may induce persistent amelioration of osteoarticular complaints, but may exacerbate cutaneous manifestations. Rheumatology 45:730-733
20. Cuchacovich R, Espinoza CG, Virk Z et al (2008) Biologic therapy (TNF-alpha antagonists)-induced psoriasis: A cytokine imbalance between TNF-alpha and IFN-alpha? J Clin Rheumatol 14:353-356